View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May 10, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Entity Central Index Key	0000946486
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,230,561
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 29,400	$ 38,722
Prepaid interest, current portion	1,435	1,710
Prepaid expenses and other current assets	500	362
Total current assets	31,335	40,794
Property and equipment, net	1,100	1,039
Restricted cash	225	225
Prepaid interest, non-current portion	2,050	2,319
Total assets	34,710	44,377
Current Liabilities:
Accounts payable	5,512	3,263
Accrued expenses	9,135	7,582
Common stock warrant liability	0	223
Total current liabilities	14,647	11,068
Long-term debt	25,000	25,000
Other liabilities	40	43
Total liabilities	39,687	36,111
Stockholders' Equity/(Deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 36,000,000 shares authorized; 8,232,053 and 8,196,011 shares issued at March 31, 2016 and December 31, 2015, respectively; 8,230,561 and 8,194,519 shares outstanding at March 31, 2016 and December 31, 2015, respectively	8	8
Additional paid-in capital	591,148	590,490
Accumulated deficit	(593,079)	(579,178)
Treasury stock (at cost); 1,492 shares	(3,054)	(3,054)
Total stockholders' equity/(deficit)	(4,977)	8,266
Total liabilities & stockholders' equity	$ 34,710	$ 44,377

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Stockholders' Equity/(Deficit):
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	36,000,000	36,000,000
Common stock, shares issued (in shares)	8,232,053	8,196,011
Common stock, shares outstanding (in shares)	8,230,561	8,194,519
Treasury stock (at cost) (in shares)	1,492	1,492

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Product sales	$ 0	$ 7
Grant revenue	75	184
Total revenues	75	191
Expenses:
Cost of product sales	0	929
Research and development	10,360	7,082
Selling, general, and administrative	3,657	3,353
Total expenses	14,017	11,364
Operating loss	(13,942)	(11,173)
Change in fair value of common stock warrant liability	223	(31)
Other income / (expense):
Interest and other income	440	233
Interest and other expense	(622)	(1,208)
Other income / (expense), net	(182)	(975)
Net loss	$ (13,901)	$ (12,179)
Net loss per common share - Basic and diluted (in dollars per share)	$ (1.70)	$ (1.96)
Weighted-average number of common shares outstanding - basic and diluted (in shares)	8,191	6,114

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flow from operating activities:
Net loss	$ (13,901)	$ (12,179)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	76	425
Change in provision for excess inventory	0	(174)
Stock-based compensation and 401(k) plan employer match	658	792
Fair value adjustment of common stock warrants	(223)	31
Amortization of discount of long-term debt	0	555
Amortization of prepaid interest	544	0
Changes in:
Inventory	0	201
Prepaid expenses and other current assets	(138)	245
Accounts payable	2,249	352
Accrued expenses	1,550	1,108
Deferred revenue	0	(43)
Other liabilities	0	27
Net cash used in operating activities	(9,185)	(8,660)
Cash flows from investing activities:
Purchase of property and equipment	(137)	(448)
Net cash used in investing activities	(137)	(448)
Cash flows from financing activities:
Repayment of equipment loans	0	(20)
Net cash (used in) provided by financing activities	0	(20)
Net decrease in cash and cash equivalents	(9,322)	(9,128)
Cash and cash equivalents - beginning of period	38,722	44,711
Cash and cash equivalents - end of period	29,400	35,583
Supplementary disclosure of cash flows information:
Interest paid	$ 22	$ 649

The Company and Description of Business	3 Months Ended
The Company and Description of Business	Mar. 31, 2016
The Company and Description of Business [Abstract]
The Company and Description of Business	Note 1 – The Company and Description of Business Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. Surfactants are produced naturally in the lung and are essential for normal respiratory function and survival. Our proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and novel drug delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. We believe that our proprietary technology platform may make it possible to develop a pipeline of surfactant products to address a variety of respiratory diseases for which there are few or no approved therapies. Our lead development program, AEROSURF^® (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a serious respiratory condition that can result in long-term respiratory problems, developmental delay and death. Premature infants born prior to 37 weeks gestational age may not have fully developed natural lung surfactant and therefore may develop RDS and need surfactant therapy to sustain life. Higher incidence and severity of RDS are correlated with younger gestational ages; however, RDS can occur at any premature gestational age. RDS is the most prevalent respiratory disease in the neonatal intensive care unit (NICU). Surfactant therapy is a life-saving treatment for RDS and the primary therapy to address an underlying surfactant deficiency. Surfactants currently available in the U.S. are animal-derived and are administered using invasive endotracheal intubation and mechanical ventilation, each of which may result in serious respiratory conditions and other complications. Intubation is associated with airway trauma and clinical instability that can extend beyond the respiratory system such as increased intracranial pressure and risk for brain injury. Mechanical ventilation is associated with ventilator-associated lung injury, chronic lung disease and increased risk of infection. To avoid these risks, many premature infants are initially treated with noninvasive respiratory support, such as nasal continuous positive airway pressure (nCPAP). Unfortunately, since nCPAP does not address the underlying surfactant deficiency associated with RDS, many premature infants respond poorly to nCPAP (typically within the first 72 hours of life) and may require intubation and delayed surfactant therapy (an outcome referred to as nCPAP failure). In addition, many premature infants with RDS who receive surfactant therapy as initial therapy are capable of breathing without mechanical ventilation, but require surfactant therapy for RDS. Because administration of surfactant therapy requires intubation, these infants generally are supported with mechanical ventilation for either a limited or extended period of time. If surfactant therapy could be administered noninvasively, neonatologists would be able to provide surfactant therapy to these premature infants without exposing them to the risks associated with intubation and mechanical ventilation. AEROSURF is an investigational combination drug/device product that combines our proprietary KL4 surfactant with our novel aerosol delivery system (ADS), which is based primarily on our capillary aerosol generator technology. We are developing AEROSURF to enable administration of aerosolized KL4 surfactant to premature infants receiving nCPAP without invasive intubation and mechanical ventilation. We believe that, if approved, AEROSURF will have the potential to transform the treatment of RDS, allow for earlier treatment of those premature infants who currently receive surfactants later in their course of treatment, decrease the morbidities and complications currently associated with surfactant administration, and reduce the number of premature infants who are subjected to invasive intubation and delayed surfactant therapy as a result of nCPAP failure. By enabling delivery of our aerosolized KL4 surfactant using noninvasive methods, we believe that AEROSURF, if approved, will address a serious unmet medical need and potentially provide transformative clinical and pharmacoeconomic benefits. The drug product component of our AEROSURF product candidate is a lyophilized (freeze-dried) dosage form of our KL4surfactant liquid instillate drug product that was approved by the U.S. Food and Drug Administration (FDA) in 2012 under the name SURFAXIN^® (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants at high risk for RDS. In the second quarter of 2015, we determined to cease commercial and manufacturing activities for SURFAXIN to focus our limited resources on advancing the AEROSURF clinical development program and our potential aerosolized KL4 surfactant pipeline. We believe that gaining the approval of SURFAXIN provided us valuable experience to support the further development of our KL4 surfactant product candidates, beginning with AEROSURF. Effective February 1, 2016, we announced the appointment of Craig Fraser to serve as our President and Chief Executive Officer. Upon recommendation of the Nomination and Governance Committee of our Board of Directors Mr. Fraser was also appointed to serve as a member of the Board, effective immediately. As part of this transition, we initiated a plan to reassess, refocus and rebrand our Company. Effective April 19, 2016, we changed our name to Windtree Therapeutics, Inc. Our common stock now trades under the symbol WINT and our new website is windtreetx.com.

Liquidity Risks and Management's Plans	3 Months Ended
Liquidity Risks and Management's Plans	Mar. 31, 2016
Liquidity Risks and Management's Plans [Abstract]
Liquidity Risks and Management's Plans	Note 3 – Liquidity Risks and Management’s Plans As of March 31, 2016, we had cash and cash equivalents of approximately $29.4 million, current accounts payable and accrued expenses of $14.6 million, including $4.1 million (of which $0.1 million is interest accrued at a rate of 12% per annum) due to Battelle Memorial Institute (Battelle) under our collaboration agreement and $25 million of long-term debt under a secured loan (Deerfield Loan) with affiliates of Deerfield Management, L.P. (Deerfield). The principal portion of the Deerfield Loan is payable in two equal installments in February 2018 (subject to potential deferral in certain circumstances) and February 2019. In addition, as of March 31, 2016, we had negative stockholders’ equity of $5.0 million. We have incurred substantial losses since inception, due to investments in research and development, manufacturing, the commercialization of SURFAXIN, and we expect to continue to incur substantial losses over the next four to five years. Before any additional financings or other transactions, we anticipate that we will have sufficient cash available to support our development programs, business operations and debt service obligations through the first quarter of 2017. The accompanying financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In the future, our ability to continue as a going concern is dependent on our ability to raise additional capital to fund our research and development programs and meet our obligations on a timely basis. To be able to raise additional capital, however, we believe that we will need to successfully complete our ongoing phase 2b clinical trial and release positive top line data in the first quarter of 2017, in accordance with our plan. If we are unable to complete the trial as planned, or if the results of our clinical trial are inconclusive, or present an unacceptable benefit/risk profile due to suboptimal efficacy and/or safety profile, we may be unable to secure the additional required capital, which could significantly limit our ability to continue as a going concern. As of March 31, 2016, the financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue in existence. To potentially mitigate the risk that we may be unable to continue as a going concern, we plan to pursue all or a combination of potential strategic alliances, collaboration agreements and other strategic transactions (including potentially a merger, acquisition or other corporate transaction). We also may seek additional capital through public or private equity offerings (including our ATM Program), which could have a dilutive impact on our stockholders and the issuance, or even potential issuance, of shares could have a negative effect on the market price of our common stock. However, a number of factors in addition to the timing and outcomes of our clinical activities, including whether we will be able to maintain compliance with the Nasdaq listing requirements, limitations on our ability to use our 2014 Universal Shelf and conditions in the broader financial markets, may present significant challenges to accessing the capital markets at a time when we would like or require. Even if we are able to secure additional capital, such financings may only be available on unattractive terms, or could result in significant dilution of stockholders’ interests. If none of the foregoing alternatives is available, or if available, we are unable to raise sufficient capital through such transactions, we may be forced to limit or cease our development activities. We have in the past collaborated with research organizations and universities to assess the potential utility of our KL4 surfactant in studies funded in part through non-dilutive grants issued by U.S. Government-sponsored drug development programs, including grants in support of initiatives related to our AEROSURF clinical program and medical and biodefense-related initiatives under programs that encourage private sector development of medical countermeasures against chemical, biological, radiological, and nuclear terrorism threat agents, and pandemic influenza, and provide a mechanism for federal acquisition of such countermeasures. Although there can be no assurance, we continue to pursue such funding opportunities and expect that we may qualify for similar programs in the future. Moreover, if we fail in the future to make any required payment under our Deerfield Loan or fail to comply with any commitments contained in the loan documents, Deerfield would be able to declare us in default regarding that indebtedness, which could result in the acceleration of the payment obligations under all or a portion of our indebtedness. Since we have pledged substantially all of our assets to secure our obligations under the Deerfield Loan, a debt default would enable the lenders to foreclose on our assets securing the debt and could significantly diminish the market value and marketability of our common stock. Our ability to secure capital under our ATM Program or pursuant to public offerings under our 2014 Universal Shelf is constrained by the value of our equity securities held by nonaffiliated persons and entities (public float), which as of May 10, 2016 is approximately $17.5 million. Our 2014 Universal Shelf was filed on Form S-3, which limits the size of primary securities offerings conducted by companies that have a public float of less than $75 million to no more than one-third of their public float in any 12-month period. Accordingly, we are presently able to raise no more than approximately $5.8 million in a primary offering under our 2014 Universal Shelf. To raise capital, we may be required to seek other forms of transactions, including, for example, under a registration statement on Form S-1, the preparation and maintenance of which would be more time-consuming and costly, or private placements, potentially with registration rights or priced at a discount to the market value of our stock, or other transactions, any of which could result in substantial equity dilution of stockholders’ interests. In addition, although we have regained compliance with the Minimum Bid Price Requirement of the Nasdaq Listing Rules, we anticipate that we may receive a delisting notice from the Nasdaq Capital Market based on our failure to maintain at least one of the requirements contained in Nasdaq Listing Rule 5550(b), specifically maintaining a minimum market capitalization of at least $35 million or stockholders’ equity of at least $2.5 million. Failure to regain compliance with at least one these requirements could lead to delisting of our Common Stock and would likely further depress the value of our stock. In addition, to be able to raise sufficient capital to support our activities in the near term through strategic alliances or other strategic transactions involving the issuance of our capital stock, or through public or private equity offerings, given our current per share market price, we expect to seek approval from our stockholders to increase the number of shares of common stock authorized for issuance under our Amended and Restated Certificate of Incorporation. In addition, if any such offering were to involve the issuance of common stock in excess of 20% of our outstanding common stock, we may be required under Nasdaq Listing Rules to seek stockholder approval before we can proceed. There can be no assurance that we would be successful in obtaining such approvals. Failure to secure the additional capital that we will need, whether from non-dilutive sources or from equity offerings, would have a material adverse impact on our business and our ability to continue as a going concern. As of March 31, 2016, we had outstanding 2.9 million pre-funded warrants issued in a July 2015 public offering, of which the entire purchase price was pre-paid upon issuance. Upon exercise of the pre-funded warrants, we would issue the shares to the holders and receive no additional proceeds. In addition, as of March 31, 2016, there were 36 million shares of common stock and 5 million shares of preferred stock authorized under our Amended and Restated Certificate of Incorporation and approximately 17.0 million shares of common stock and 5 million shares of preferred stock were available for issuance and not otherwise reserved.

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 4 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U.S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Severance Effective February 1, 2016, the Employment Agreement between ourselves and John G. Cooper, our then President and Chief Executive Officer (the Former CEO) was terminated. In connection therewith, upon execution by the Former CEO of a plenary release in form satisfactory to us, he became entitled under his Employment Agreement to the following severance and other benefits, in addition to any vested benefits under our company plans or policies: (i) a pro rata bonus equal to a percentage of his Annual Bonus Amount (as defined in the Employment Agreement) determined by dividing the aggregate bonuses paid to other contract executives for the year 2016 by the aggregate target bonuses of such other contract executives for 2016, and further prorated for the number of days the Former CEO was employed during 2016, payable at the time that other contract executives are paid bonuses with respect to 2016; (ii) a severance amount equal to the sum of the Former CEO’s base salary then in effect and his Annual Bonus Amount, payable in equal installments through August 1, 2017 (the Severance Period); and (iii) all stock options held by the Former CEO will continue to vest during the Severance Period, and continue to be exercisable for up to 36 months after the date of termination. From and after the end of the Severance Period, the Former CEO will forfeit all of his unvested stock options in accordance with the terms of the 2011 Plan. The Former CEO also is subject to non-competition and non-solicitation restrictions for 12 months and 18 months, respectively, after the date of termination under a separate confidentiality agreement. All of our obligations under the Employment Agreement will cease if at any time during the Severance Period the Former CEO engages in a material breach of the Employment Agreement and fails to cure such breach within five business days after receipt from us of notice of such breach. For the three months ended March 31, 2016, we incurred a severance charge of $1.2 million in selling, general and administrative expense under the terms of the Former CEO’s Employment Agreement, including $0.2 million related to stock option expense for those options that will continue to vest through the Severance Period. Of the $1.0 million in severance not related to stock-based compensation, $0.1 million was paid during the first quarter of 2016. The remaining $0.9 million will be paid through August 1, 2017. Restructuring Plan In April 2015, we implemented a restructuring plan to voluntarily cease the commercialization of SURFAXIN and focus our resources on the development of our aerosolized KL4 surfactant pipeline for respiratory diseases, beginning with AEROSURF. As part of the restructuring plan, we ceased manufacturing activities at our manufacturing facility in Totowa, New Jersey (Totowa Facility), which we closed upon the expiration of our lease on June 30, 2015. The total severance cost for all impacted employees is $2.9 million, of which $1.0 million was accrued as of December 31, 2014 for Totowa employees. The remaining $1.9 million was charged to expense through the second quarter of 2015 ($1.0 million to research and development expenses and $0.9 million to selling, general and administrative expenses). We paid $2.6 million and $0.1 million of the severance and retention benefits during 2015 and the first quarter of 2016, respectively. The remaining $0.2 million will be paid during the second quarter of 2016. Research and development expense We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred. Net loss per common share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the quarters ended March 31, 2016 and 2015, the number of shares of common stock potentially issuable upon the exercise of stock options and warrants was 9.2 million and 1.7 million shares, respectively. As of March 31, 2016 and 2015, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share. In accordance with Accounting Standards Codification Topic 260 (ASC 260), Earnings per Share, when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of these warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of warrants classified as derivative liabilities. For the quarters ended March 31, 2016 and 2015, the effect of the adjustments for warrants classified as derivative liabilities was anti-dilutive. We do not have any components of other comprehensive income (loss). Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or are available to be issued). ASU No. 2014-15 provides guidance to an organization’s management, with principles and definitions intended to reduce diversity in the timing and content of disclosures commonly provided by organizations in the footnotes of their financial statements. ASU No. 2014-15 is effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. While we currently intend to adopt the standard as of December 31, 2016, if this standard had been adopted as of March 31, 2016, management of the Company believes that it would have concluded there is substantial doubt about the Company’s ability to continue as a going concern one year from the date of filing of this Form 10-Q. See Note 3 for additional information on our liquidity risks and management’s plans. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, amending the accounting for leases in Leases (ASU Topic 482). This ASU requires lessees to put most leases on their balance sheets but recognize expenses in the income statement in a manner similar to current accounting standards. The ASU is effective for the annual period ending December 31, 2019 and interim periods thereafter. Early adoption is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. We are currently evaluating the effect that ASU 2016-02 will have on our consolidated financial statements and related disclosures. In March 2016, the FASB issued Accounting Standards Update 2016-09, Compensation- Stock Compensation (ASU 2016-09). ASU 2016-09 was issued as part of the FASB Simplification Initiative. This update addresses the income tax effects of stock-based payments and eliminates the windfall pool concept, as all of the tax effects related to stock-based payments will now be recorded at settlement (or expiration) through the income statement. The new guidance also permits entities to make an accounting policy election for the impact of forfeitures on the recognition of expense for stock-based payment awards. Forfeitures can be estimated or recognized when they occur. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that reporting period. Early adoption is permitted in any interim or annual period, with any adjustment reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect that ASU 2016-09 will have on our consolidated financial statements and related disclosures.

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2016

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

Note 5 – Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets and liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	March 31, 2016		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	29,400	$	29,400	$	–	$	–
Certificate of deposit		225		225		–		–
Total Assets	$	29,625	$	29,625	$	–	$	–

	Fair Value		Fair value measurement using
	December 31, 2015		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	38,722	$	38,722	$	–	$	–
Certificate of deposit		225		225		–		–
Total Assets	$	38,947	$	38,947	$	–	$	–

Liabilities:
Common stock warrant liability	$	223	$	–	$	–	$	223

The tables below summarize the activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2016 and 2015:

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2015	$	223
Change in fair value of common stock warrant liability		(223	)
Balance at March 31, 2016	$	–

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2014	$	1,258
Change in fair value of common stock warrant liability		31
Balance at March 31, 2015	$	1,289

The significant unobservable inputs for a trinomial model used in the fair value measurement of the common stock warrants measured on a recurring basis are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. In addition to the significant unobservable inputs noted above, certain fair value measurements also take into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in certain of the warrants. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.

Significant Unobservable Input Assumptions of Level 3 Valuations	March 31, 2016		March 31, 2015

Historical volatility		–		61 %
Expected term (in years)		–		0.9
Risk-free interest rate		–		0.25 %

Fair Value of Long-Term Debt

At March 31, 2016 and December 31, 2015, the estimated fair value of the Deerfield Loan (see, Note 7, “Deerfield Loan”) approximated the carrying value of $25.0 million. The estimated fair value of the Deerfield Loan is based on discounting the future contractual cash flows to the present value at the valuation date. This analysis utilizes certain Level 3 unobservable inputs, including current cost of capital. Considerable judgment is required to interpret market data and to develop estimates of fair value. The estimates presented are not necessarily indicative of amounts we could realize in a current market exchange. The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U.S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Severance	Severance Effective February 1, 2016, the Employment Agreement between ourselves and John G. Cooper, our then President and Chief Executive Officer (the Former CEO) was terminated. In connection therewith, upon execution by the Former CEO of a plenary release in form satisfactory to us, he became entitled under his Employment Agreement to the following severance and other benefits, in addition to any vested benefits under our company plans or policies: (i) a pro rata bonus equal to a percentage of his Annual Bonus Amount (as defined in the Employment Agreement) determined by dividing the aggregate bonuses paid to other contract executives for the year 2016 by the aggregate target bonuses of such other contract executives for 2016, and further prorated for the number of days the Former CEO was employed during 2016, payable at the time that other contract executives are paid bonuses with respect to 2016; (ii) a severance amount equal to the sum of the Former CEO’s base salary then in effect and his Annual Bonus Amount, payable in equal installments through August 1, 2017 (the Severance Period); and (iii) all stock options held by the Former CEO will continue to vest during the Severance Period, and continue to be exercisable for up to 36 months after the date of termination. From and after the end of the Severance Period, the Former CEO will forfeit all of his unvested stock options in accordance with the terms of the 2011 Plan. The Former CEO also is subject to non-competition and non-solicitation restrictions for 12 months and 18 months, respectively, after the date of termination under a separate confidentiality agreement. All of our obligations under the Employment Agreement will cease if at any time during the Severance Period the Former CEO engages in a material breach of the Employment Agreement and fails to cure such breach within five business days after receipt from us of notice of such breach. For the three months ended March 31, 2016, we incurred a severance charge of $1.2 million in selling, general and administrative expense under the terms of the Former CEO’s Employment Agreement, including $0.2 million related to stock option expense for those options that will continue to vest through the Severance Period. Of the $1.0 million in severance not related to stock-based compensation, $0.1 million was paid during the first quarter of 2016. The remaining $0.9 million will be paid through August 1, 2017.
Restructuring Plan	Restructuring Plan In April 2015, we implemented a restructuring plan to voluntarily cease the commercialization of SURFAXIN and focus our resources on the development of our aerosolized KL4 surfactant pipeline for respiratory diseases, beginning with AEROSURF. As part of the restructuring plan, we ceased manufacturing activities at our manufacturing facility in Totowa, New Jersey (Totowa Facility), which we closed upon the expiration of our lease on June 30, 2015. The total severance cost for all impacted employees is $2.9 million, of which $1.0 million was accrued as of December 31, 2014 for Totowa employees. The remaining $1.9 million was charged to expense through the second quarter of 2015 ($1.0 million to research and development expenses and $0.9 million to selling, general and administrative expenses). We paid $2.6 million and $0.1 million of the severance and retention benefits during 2015 and the first quarter of 2016, respectively. The remaining $0.2 million will be paid during the second quarter of 2016.
Research and development expense	Research and development expense We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred.
Net loss per common share	Net loss per common share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the quarters ended March 31, 2016 and 2015, the number of shares of common stock potentially issuable upon the exercise of stock options and warrants was 9.2 million and 1.7 million shares, respectively. As of March 31, 2016 and 2015, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share. In accordance with Accounting Standards Codification Topic 260 (ASC 260), Earnings per Share, when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of these warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of warrants classified as derivative liabilities. For the quarters ended March 31, 2016 and 2015, the effect of the adjustments for warrants classified as derivative liabilities was anti-dilutive. We do not have any components of other comprehensive income (loss).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or are available to be issued). ASU No. 2014-15 provides guidance to an organization’s management, with principles and definitions intended to reduce diversity in the timing and content of disclosures commonly provided by organizations in the footnotes of their financial statements. ASU No. 2014-15 is effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. While we currently intend to adopt the standard as of December 31, 2016, if this standard had been adopted as of March 31, 2016, management of the Company believes that it would have concluded there is substantial doubt about the Company’s ability to continue as a going concern one year from the date of filing of this Form 10-Q. See Note 3 for additional information on our liquidity risks and management’s plans. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, amending the accounting for leases in Leases (ASU Topic 482). This ASU requires lessees to put most leases on their balance sheets but recognize expenses in the income statement in a manner similar to current accounting standards. The ASU is effective for the annual period ending December 31, 2019 and interim periods thereafter. Early adoption is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. We are currently evaluating the effect that ASU 2016-02 will have on our consolidated financial statements and related disclosures. In March 2016, the FASB issued Accounting Standards Update 2016-09, Compensation- Stock Compensation (ASU 2016-09). ASU 2016-09 was issued as part of the FASB Simplification Initiative. This update addresses the income tax effects of stock-based payments and eliminates the windfall pool concept, as all of the tax effects related to stock-based payments will now be recorded at settlement (or expiration) through the income statement. The new guidance also permits entities to make an accounting policy election for the impact of forfeitures on the recognition of expense for stock-based payment awards. Forfeitures can be estimated or recognized when they occur. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that reporting period. Early adoption is permitted in any interim or annual period, with any adjustment reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect that ASU 2016-09 will have on our consolidated financial statements and related disclosures.

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value of Financial Instruments [Abstract]

Assets and liabilities measured at fair value

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	March 31, 2016		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	29,400	$	29,400	$	–	$	–
Certificate of deposit		225		225		–		–
Total Assets	$	29,625	$	29,625	$	–	$	–

	Fair Value		Fair value measurement using
	December 31, 2015		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	38,722	$	38,722	$	–	$	–
Certificate of deposit		225		225		–		–
Total Assets	$	38,947	$	38,947	$	–	$	–

Liabilities:
Common stock warrant liability	$	223	$	–	$	–	$	223

Common stock warrants measured at Level 3 inputs on recurring basis

The tables below summarize the activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2016 and 2015:

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2015	$	223
Change in fair value of common stock warrant liability		(223	)
Balance at March 31, 2016	$	–

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2014	$	1,258
Change in fair value of common stock warrant liability		31
Balance at March 31, 2015	$	1,289

Significant unobservable input assumption used for valuation

Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.

Significant Unobservable Input Assumptions of Level 3 Valuations	March 31, 2016		March 31, 2015

Historical volatility		–		61 %
Expected term (in years)		–		0.9
Risk-free interest rate		–		0.25 %

Liquidity Risks and Management's Plans (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($) Installment shares	Dec. 31, 2015 USD ($) shares	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Class of Warrant or Right [Line Items]
Cash and cash equivalents	$ 29,400	$ 38,722	$ 35,583	$ 44,711
Current accounts payable and accrued expenses	14,600
Long-term debt	$ 25,000	25,000
Number of principal debt repayment installments \| Installment	2
Maximum amount can be raised from public offerings	$ 5,800
Stockholders equity	$ (4,977)	$ 8,266
Excess percentage of common stock issued to acquire additional capital	20.00%
Common stock, shares authorized (in shares) \| shares	36,000,000	36,000,000
Preferred stock authorized (in shares) \| shares	5,000,000	5,000,000
Common stock available for future issuance (in shares) \| shares	17,000,000
Preferred stock reserved for future issuance (in shares) \| shares	5,000,000
ATM Program [Member]
Class of Warrant or Right [Line Items]
Value of equity securities held by non affiliates and entities	$ 17,500
Maximum public float considered for primary securities offerings	$ 75,000
Period consider for maximum public float	12 months
ATM Program [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Market capitalization	$ 35,000
Stockholders equity	2,500
Battelle - 2014 Collaboration Agreement [Member]
Class of Warrant or Right [Line Items]
Current accounts payable and accrued expenses	4,100
Accrued interest	$ 100
Interest rate percentage	12.00%
Prefunded Warrants [Member] \| July 2015 Public Offering [Member]
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) \| shares	2,900,000

Summary of Significant Accounting Policies (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended				12 Months Ended
	Feb. 01, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Aug. 01, 2017	Jun. 30, 2016
Summary of Significant Accounting Policies [Abstract]
Number of shares of common stock potentially issuable upon the exercise of stock options and warrants (in shares)		9.2		1.7
Former CEO's Employment Agreement [Member]
Restructuring Cost and Reserve [Line Items]
Maximum period after termination for stock options to be exercisable	36 months
Period of non-competition restrictions after termination	12 months
Period of non-solicitation restrictions after termination	18 months
Period for cure of breach	5 days
Employee severance cost		$ 1.2
Severance and retention benefits paid		0.1
Former CEO's Employment Agreement [Member] \| Subsequent Event [Member]
Restructuring Cost and Reserve [Line Items]
Severance and retention benefits to be paid in future periods							$ 0.9
Totowa Employees [Member]
Restructuring Cost and Reserve [Line Items]
Employee severance cost					$ 2.9
Employee severance cost charged to expense			$ 1.9
Accrued severance cost amount					$ 1.0
Severance and retention benefits paid		0.1				$ 2.6
Totowa Employees [Member] \| Research and Development Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Employee severance cost charged to expense			1.0
Totowa Employees [Member] \| Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Employee severance cost charged to expense			$ 0.9
Totowa Employees [Member] \| Subsequent Event [Member]
Restructuring Cost and Reserve [Line Items]
Severance and retention benefits to be paid in future periods								$ 0.2
Stock Option Expense [Member] \| Former CEO's Employment Agreement [Member]
Restructuring Cost and Reserve [Line Items]
Employee severance cost		0.2
Not Related to Stock-based Compensation [Member] \| Former CEO's Employment Agreement [Member]
Restructuring Cost and Reserve [Line Items]
Employee severance cost		$ 1.0

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Liabilities [Abstract]
Fair value of loan	$ 25,000	$ 25,000
Recurring [Member]
Assets [Abstract]
Fair Value	29,625	38,947
Recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	29,625	38,947
Recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Cash and cash equivalents [Member]
Assets [Abstract]
Fair Value	29,400	38,722
Recurring [Member] \| Cash and cash equivalents [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	29,400	38,722
Recurring [Member] \| Cash and cash equivalents [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Cash and cash equivalents [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Certificate of Deposit [Member]
Assets [Abstract]
Fair Value	225	225
Recurring [Member] \| Certificate of Deposit [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	225	225
Recurring [Member] \| Certificate of Deposit [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Certificate of Deposit [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	$ 0	0
Recurring [Member] \| Common Stock Warrant Liability [Member]
Liabilities [Abstract]
Fair Value		223
Recurring [Member] \| Common Stock Warrant Liability [Member] \| Level 1 [Member]
Liabilities [Abstract]
Fair Value		0
Recurring [Member] \| Common Stock Warrant Liability [Member] \| Level 2 [Member]
Liabilities [Abstract]
Fair Value		0
Recurring [Member] \| Common Stock Warrant Liability [Member] \| Level 3 [Member]
Liabilities [Abstract]
Fair Value		$ 223

Common Stock Warrant Liability (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Feb. 22, 2011
Estimated fair value of warrants accounted for as derivative liabilities [Abstract]
Fair value of warrants	$ 0		$ 223
Number of warrants exercised (in shares)	0	0
2011 Warrants [Member]
Estimated fair value of warrants accounted for as derivative liabilities [Abstract]
Warrants issuance date	Feb. 22, 2011
Warrants expiration date	Feb. 22, 2016
Fair value of warrants				$ 8,000
Exercise price of warrants (in dollars per share)	$ 2.66

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References + Details

Deerfield Loan (Details) $ in Thousands	3 Months Ended
Deerfield Loan (Details) $ in Thousands	Mar. 31, 2016 USD ($) Installment	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)
Carrying value of Facility Agreement [Abstract]
Note Payable	$ 25,000		$ 25,000
Deerfield Debt Restructuring [Member]
Carrying value of Facility Agreement [Abstract]
Number of loan installments \| Installment	2
Deferred period for loan payment	1 year
Principal amount of loan outstanding payable in February 2018	$ 12,500
Principal amount of loan outstanding payable in February 2019	$ 12,500
Cash interest rate under loan facility	8.75%	8.75%
Principal amount of loan payable, prepayment amount	$ 5,000
Principal amount of loan payable, future interest obligation	5,000
Deerfield Management Company [Member]
Interest expense [Abstract]
Cash interest expense	0	$ 647
Amortization of prepaid interest expense	544	0
Non-cash amortization of debt discount	0	554
Amortization of debt costs	0	5
Total interest expense	$ 544	$ 1,206

Stock Options and Stock-Based Employee Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Options and Stock-Based Employee Compensation [Abstract]
Weighted-average vesting period of stock options	3 years
Weighted-average assumptions used in estimating fair value of stock options [Abstract]
Weighted average expected volatility	79.00%	83.00%
Weighted average expected term	5 years 8 months 12 days	5 years 7 months 6 days
Weighted average risk-free interest rate	1.40%	1.50%
Expected dividends	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation	$ 603	$ 599
Research & Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation	182	213
Selling, General & Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation	$ 421	$ 386

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2016
Basis of Presentation [Abstract]
Basis of Presentation	Note 2 – Basis of Presentation The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form 10‑Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete consolidated financial statements. All share and per share information in this Quarterly Report related to our common stock has been retroactively restated to reflect the reverse stock split and reduction in authorized shares that was approved by our Board of Directors and stockholders and made effective on January 22, 2016. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. There have been no changes to our critical accounting policies since December 31, 2016. For a discussion of our accounting policies, see, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” in the Notes to Consolidated Financial Statements in our 2015 Form 10-K, as amended (2015 Form 10-K). Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

Common Stock Warrant Liability	3 Months Ended
Common Stock Warrant Liability	Mar. 31, 2016
Common Stock Warrant Liability [Abstract]
Common Stock Warrant Liability	Note 6 – Common Stock Warrant Liability We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity’s Own Equity (ASC 815), either as derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. On February 22, 2011, we issued registered warrants (2011 Warrants) that expired on February 22, 2016 and had a fair value at issuance of $8.0 million. These warrants contained anti-dilution provisions that in certain circumstances would adjust the exercise price if we issued any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. Although by their express terms, these warrants were not subject to potential cash settlement, due to the nature of the anti-dilution provisions, they were classified as derivative liabilities and reported, at each balance sheet date until their expiration, at estimated fair value determined using a trinomial pricing model. The exercise price of these warrants was adjusted downward to $2.66 per share at the time of the July 2015 public offering. No warrants were exercised during the three months ended March 31, 2016 and 2015. Changes in the estimated fair value of warrants classified as derivative liabilities are reported in the accompanying Consolidated Statement of Operations as the “Change in fair value of common stock warrants.” The change for the quarter ended March 31, 2016 represents the write-off of the derivative liability upon expiration of the underlying warrants in February 2016.

Fair Value of Financial Instruments, Level 3 Rollforward (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair value measurements of common stock warrants using significant unobservable inputs (level 3) [Roll Forward]
Balance at beginning of period	$ 223
Balance at end of period	0
Level 3 [Member]
Fair value measurements of common stock warrants using significant unobservable inputs (level 3) [Roll Forward]
Balance at beginning of period	223	$ 1,258
Change in fair value of common stock warrant liability	(223)	31
Balance at end of period	$ 0	$ 1,289

Fair Value of Financial Instruments, Significant Unobservable input assumptions of Level 3 valuations (Details) - Level 3 [Member]	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Significant Unobservable Input Assumptions of Level 3 Valuations [Abstract]
Historical volatility	0.00%	61.00%
Expected term	0 years	10 months 24 days
Risk-free interest rate	0.00%	0.25%